CAMBRIDGE, Mass., July 29, 2024 /PRNewswire/ -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced participation in two investor conferences in August: BTIG virtual Biotechnology Conference, August 5-6, 2024, and Canaccord Genuity (CG) 44^th Annual Growth Conference, August 13-14, 2024 in Boston.

• BTIG Biotechnology Conference
  John Butler, Chief Executive Officer, will participate in a fireside chat on Tuesday, August 6, at 8:00 am EST.

• CG 44^th Annual Growth Conference
  Mr. Butler will present on Wednesday, August 14 at 8:30 a.m. EST. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
This email address is being protected from spambots. You need JavaScript enabled to view it.